Form 8-K - Current report:
SEC Accession No. 0001662774-24-000010
Filing Date
2024-11-13
Accepted
2024-11-13 16:15:04
Documents
14
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K qncx-20241113.htm   iXBRL 8-K 27769
2 EX-99.1 exhibit991-q324.htm EX-99.1 109190
  Complete submission text file 0001662774-24-000010.txt   275544

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qncx-20241113.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qncx-20241113_lab.xml EX-101.LAB 22534
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qncx-20241113_pre.xml EX-101.PRE 13048
16 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20241113_htm.xml XML 2836
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

EIN.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 241454412
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)